Our Company

TALLC is a pre-clinical stage biopharmaceutical company developing our new mechanism medicines to treat acute and chronic conditions in the eye.

Our Mission

To Improve the Lives of Patients by Inventing and Developing Valuable New Ophthalmic Medicines

Our Vision

To be a leading provider of pipeline opportunities in ophthalmics enabling better clinical and commercial outcomes.

Our Advantage

Our pipeline of new mechanism synergistic API, enabled for pan-ocular delivery by our SmartCelleTM and AmyloFlexTMdelivery platforms, developed by our expert team of scientist and industry professionals.

Our Programs

Largely virtual, the high experienced TALLC team will first focus on SmartCelle TA-A001, a micellar formulation of our novel CB2 receptor specific drug candidate:

  • As a topically instilled eye drop for the severe pain and inflammation that occurs after cross-linking surgery for keratoconus

  • As a topical treatment to avoid the pain and inflammation resulting from PRK, LASIK, SMILE and Cataract surgeries
  • TALLC is also developing extended release formulations of our pipeline candidates for treatment of Dry-Eye Disease, Uveitis, AMD and Glaucoma

Meet the team



Board Of


Phone: 514 883 3447

Email: info@tallcinc.com


TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC and IACTA to present at the H.C. Wainwright Bioconnect Conference: January 10-13, 2022

TALLC will present details of the SmartCelle insoluble drug delivery platform for ocular, parenteral and oral delivery and an update on t…https://lnkd.in/gAwAqwnQ

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020